I don’t know. What you see as deep and diverse, I see as random and haphazard. There are a few large shareholders, and then a lot of individuals who don’t really have that many shares in the grand scheme of things. Adding more people into the mix of any type of effort doesn’t lead to cohesion – – quite the opposite. And nothing against Paulson - but they’re not exactly McKinsey or Morgan Stanley.

The problem as I see it, is that uncertainty usually is the worst ingredient for a stock. And all this group has done is introduce a lot of uncertainty as to what their intentions are. I would love to see them come out with a statement that says they will be patient to see how the ongoing trials in Brazil and the clinical process in India plays out – – and to the extent those bear no fruit, they will bring some type of cohesive message.

And if we get nothing from PI, Brazil, or India - I’ll be open to other options. But for now, it’s noise -
and downward pressure on our valuation.